Shane Howatt, PA
Medical · Lufkin, TXNPI 1578572152
Payments from drug & device makers
Across 330 payments — averaging $16.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$811
- Lilly USA, LLC$593
- Pfizer$495
- GSK$470
- Exact Sciences$429
- Johnson & Johnson$377
- plus $2K from 25 others
What the payments were for
- Food & beverage$5,567100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 47 | $811 |
| Lilly USA, LLC | 40 | $593 |
| Pfizer | 26 | $495 |
| GSK | 26 | $470 |
| Exact Sciences | 26 | $429 |
| Johnson & Johnson | 26 | $377 |
| Bayer | 19 | $359 |
| AstraZeneca | 21 | $356 |
| E.r. Squibb & Sons, L.L.C. | 17 | $291 |
| Sanofi-aventis U.S. LLC | 17 | $233 |
| Boehringer Ingelheim | 10 | $192 |
| Amgen | 10 | $164 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $107 |
| AbbVie | 6 | $100 |
| Vifor Pharma, Inc. | 4 | $88 |
| Otsuka America Pharmaceutical, Inc. | 3 | $63 |
| Mylan Specialty L.p. | 2 | $61 |
| Novartis | 3 | $53 |
| Dexcom, Inc. | 2 | $50 |
| Shield Therapeutics Inc | 2 | $33 |
| Amarin Pharma, Inc. | 2 | $33 |
| Merck | 2 | $32 |
| Abbott | 2 | $31 |
| Viatris Specialty LLC | 1 | $29 |
| Genentech USA, Inc. | 2 | $24 |
| Biogen | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| Almatica Pharma LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PREVNAR 20$129
- COMIRNATY$129
- ABRYSVO$129
How this compares
$5,567 in reported general payments places this provider in the 85th percentile of 1,490 medical providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 331 | $428,482 |
| EliquisApixaban | 179 | $207,993 |
| JardianceEmpagliflozin | 170 | $164,914 |
| XareltoRivaroxaban | 108 | $110,752 |
| TrulicityDulaglutide | 64 | $86,503 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 70 | $58,051 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 64 | $55,564 |
| FarxigaDapagliflozin Propanediol | 65 | $52,860 |
| MounjaroTirzepatide | 36 | $39,221 |
| Breo ElliptaFluticasone/Vilanterol | 52 | $33,740 |
| MyrbetriqMirabegron | 44 | $27,707 |
| RybelsusSemaglutide | 17 | $26,783 |
| LinzessLinaclotide | 39 | $25,055 |
| EntrestoSacubitril/Valsartan | 27 | $24,122 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $21,313 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $811 | $455,265348 claims |
| PfizerEliquis | $495 | $207,993179 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $192 | $179,097198 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $593 | $125,724100 claims |
| Johnson & JohnsonXarelto, Invokana | $377 | $124,514119 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $470 | $91,791122 claims |
| AstraZenecaFarxiga, Symbicort | $356 | $63,37690 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $233 | $60,07490 claims |
| AbbVieLinzess | $100 | $25,05539 claims |
| NovartisEntresto | $53 | $24,12227 claims |
| MerckJanuvia, Janumet Xr | $32 | $22,39930 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,490 medical providers in Texas.
Other medical in Lufkin
- Jose de la CerdaSan Antonio$1.1M
- Mark DavisFort Worth$1M
- Joey Dixon-JulianBoerne$458K
- Terry FaleyeKingwood$243K
- Kimberly PoarchDallas$166K
- Erin DuhaimeDallas$150K
- Courtney AldridgeSan Antonio$129K
- Shakira CabreraSan Antonio$116K
- Danny DeckardDallas$101K
- Janine ShinnDallas$84K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.